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www.jacc-interventions.org to view.Expanding Indications of Transcatheter Heart Valve Interventions 1777
Fabien Praz, Stephan Windecker, Christoph Huber, Thierry Carrel, Peter WenaweserSEE ADDITIONAL CONTENT ONLINESTRUCTURAL A Randomized Evaluation of the SAPIEN XT Transcatheter Heart Valve System in Patients
With Aortic Stenosis Who Are Not Candidates for Surgery1797John G. Webb, Darshan Doshi, Michael J. Mack, Raj Makkar, Craig R. Smith,
Augusto D. Pichard, Susheel Kodali, Samir Kapadia, D. Craig Miller, Vasilis Babaliaros,
Vinod Thourani, Howard C. Herrmann, Mark Bodenhamer, Brian K. Whisenant,
Stephen Ramee, Hersh Maniar, Jr., Dean Kereiakes, Ke Xu, Wael A. Jaber, Venu Menon,
E. Murat Tuzcu, David Wood, Lars G. Svensson, Martin B. LeonThe PARTNER (Placement of Aortic Transcatheter Valves) II trial cohort B compared the lower-
proﬁle SAPIEN XT versus SAPIEN transcatheter heart valve (Edwards Lifesciences, Irvine, California)
in inoperable patients with severe aortic stenosis undergoing transcatheter aortic valve
replacement (TAVR). Major vascular complications were higher at 30 days in patients undergoing
TAVR with SAPIEN compared with SAPIEN XT (15.2% vs. 9.5%; p ¼ 0.04). Bleeding requiring blood
transfusions was more frequent with SAPIEN compared with SAPIEN XT (10.6% vs. 5.3%; p ¼
0.02). At 1-year follow-up, all-cause mortality, major stroke, or rehospitalization was similar
(37.7% SAPIEN vs. 37.2% SAPIEN XT; noninferiority p < 0.002). Further improvements in
transcatheter valve design may lead to superior patient outcomes.n EDITORIAL COMMENT
Transcatheter Aortic Valve Replacement Is Growing Up, But Kids Do the Darndest Things 1807
Blase A. CarabelloCONTINUED ON PAGE A-21
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DECEMBER 21, 2015 VOLUME 8, NUMBER 14Outcomes After Transcatheter Aortic Valve Replacement Using a Novel
Balloon-Expandable Transcatheter Heart Valve: A Single-Center Experience1809Oliver Husser, Costanza Pellegrini, Thorsten Kessler, Christof Burgdorf, Hannah Thaller,
N. Patrick Mayr, Ilka Ott, Albert M. Kasel, Heribert Schunkert, Adnan Kastrati,
Christian HengstenbergData after transcatheter aortic valve replacement (TAVR) with the novel balloon-expandable
SAPIEN 3 (Edwards Lifesciences, Irvine, California) are limited. In this analysis of 250 patients
undergoing TAVR, follow-up at 30 days was assessed according to the updated Valve Academic
Research Consortium-2 (VARC-2) criteria. The authors found favorable outcome with very low
rates of clinical adverse events with the VARC-2 composite early safety endpoint observed in only
25 patients (10%). Interventions resulted in high rates of device success in 244 patients (97.6%);
however, the need for pacemaker implantation seems to be more frequent compared with the
SAPIEN XT prosthesis.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Sapien 3: A Triple Threat to Aortic Stenosis 1817
Saibal Kar, Rahul Sharma
Transcatheter Pulmonary Valve Replacement With the Edwards Sapien System:
The Toronto Experience1819William M. Wilson, Lee N. Benson, Mark D. Osten, Ashish Shah, Eric M. HorlickThis is a retrospective, single-center review of the use of the Edwards Sapien system in the pulmonic
position. Twenty-ﬁve patients were identiﬁed. Technical success was high (96%). Procedural
complications were low. At a mean follow-up of 3.5  2.1 years, there was high freedom from
reintervention (96%). There were no cases of endocarditis and no stent fractures. There was no
change in valve gradients nor pulmonary regurgitation severity during follow-up. The Edwards
Sapien system is a viable and durable option for percutaneous pulmonary valve implantation in
this single-center study.n EDITORIAL COMMENT
Off-Label, On-Target: Transcatheter Pulmonary Valve Implantation
With the SAPIEN Valve1828Dennis W. Kim
A New Transcatheter Aortic Valve Replacement System for Predominant Aortic
Regurgitation Implantation of the J-Valve and Early Outcome1831Lai Wei, Huan Liu, Liming Zhu, Ye Yang, Jiayu Zheng, Kefang Guo, Hong Luo,
Weipeng Zhao, Xue Yang, Aikebaier Maimaiti, Chunsheng WangTranscatheter aortic valve replacement has been proved to be an efﬁcient treatment for aortic valve
disease in high-risk patients. However, most transcatheter aortic valve prostheses were designed for
patients with aortic stenosis. Predominant aortic regurgitation without signiﬁcant valve calciﬁcation
remains a technological challenge because of the uncertainty in anchoring the valve. In this study, we
introduced a new-generation device, the J-Valve prosthesis (JieCheng Medical Technology Co., Ltd.,
Suzhou, China), and report the feasibility and early outcomes of its implantation in 6 patients with
predominant aortic regurgitation without signiﬁcant valve calciﬁcation.CONTINUED ON PAGE A-22
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DECEMBER 21, 2015 VOLUME 8, NUMBER 14Transfemoral Implantation of a Fully Repositionable and Retrievable
Transcatheter Valve for Noncalciﬁed Pure Aortic Regurgitation1842Joachim Schofer, Fabian Nietlispach, Klaudija Bijuklic, Antonio Colombo,
Fernando Gatto, Federico De Marco, Antonio Mangieri, Lorenz Hansen, Giuseppe Bruschi,
Neil Ruparelia, Friedrich-Christian Rieß, Franscesco Maisano, Azeem LatibThe authors evaluated the repositionable and retrievable Direct Flow Medical (DFM) transcatheter
aortic valve for the treatment of high surgical risk patients with noncalciﬁed native pure aortic
regurgitation (AR). Eleven high-risk patients were included. Implantation of the DFM valve was
associated with none or trivial paravalvular regurgitation in 10 of 11 patients. One patient had a
dislocation of the prosthesis 3 days post-intervention and was successfully converted to surgical
aortic valve replacement. This study reports the feasibility of transfemoral treatment of pure
native AR with the DFM valve in selected patients, which needs to be conﬁrmed in a larger study.n EDITORIAL COMMENT
Transcatheter Options for the Treatment of Noncalciﬁed Aortic Regurgitation 1850
John G. Webb, Nay HtunCORONARY The Beneﬁts Conferred by Radial Access for Cardiac Catheterization Are Offset
by a Paradoxical Increase in the Rate of Vascular Access Site Complications
With Femoral Access: The Campeau Radial Paradox1854Lorenzo Azzalini, Kunle Tosin, Malorie Chabot-Blanchet, Robert Avram, Hung Q. Ly,
Benoit Gaudet, Richard Gallo, Serge Doucet, Jean-François Tanguay, Réda Ibrahim,
Jean C. Grégoire, Jacques Crépeau, Raoul Bonan, Pierre de Guise, Mohamed Nosair,
Jean-François Dorval, Gilbert Gosselin, Philippe L. L’Allier, Marie-Claude Guertin,
Anita W. Asgar, E. Marc JolicœurThe femoral arterial puncture is a tactful intervention that requires knowledge, skills, and practice.
Following the relatively recent widespread adoption of radial access, the femoral route is now
used less often. This has led to an increase in the rate of vascular access site complications when
femoral access is utilized, which in turn has offset the beneﬁt conferred by radial access at a
population level. The existence of this radial paradox should be taken into consideration,
especially among trainees and default radial operators.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Proﬁciency With Vascular Access: Don’t Rob Peter to Pay Paul 1865
Sunil V. Rao, Jim NolanCONTINUED ON PAGE A-23
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DECEMBER 21, 2015 VOLUME 8, NUMBER 14Transradial Versus Transfemoral Access in Patients Undergoing Rescue
Percutaneous Coronary Intervention After Fibrinolytic Therapy1868Mitul B. Kadakia, Sunil V. Rao, Lisa McCoy, Paramita S. Choudhuri,
Matthew W. Sherwood, Scott Lilly, Taisei Kobayashi, Daniel M. Kolansky,
Robert L. Wilensky, Robert W. Yeh, Jay GiriAlthough radial access has been shown to reduce bleeding and mortality in ST-segment elevation
myocardial infarction (STEMI), little is known about the role of radial access in rescue
percutaneous coronary intervention (PCI). Using the National Cardiovascular Data Registry’s
CathPCI Registry, the authors examined 9,494 STEMI patients undergoing rescue PCI and found
that 14.3% of procedures were performed with radial access. Inverse probability of treatment
weighting-adjusted analysis demonstrated a signiﬁcantly lower risk of bleeding in the radial access
group (odds ratio [OR]: 0.67; 95% conﬁdence interval [CI]: 0.52 to 0.87; p ¼ 0.003), but no
difference in in-hospital mortality (OR: 0.93; 95% CI: 0.61 to 1.44; p ¼ 0.75). Gastrointestinal
bleeding was also less frequent in the radial group (OR: 0.23; 95% CI: 0.05 to 0.98; p ¼ 0.05),
making it impossible to rule out the effect of unmeasured confounders on this analysis.n EDITORIAL COMMENT
Radial Access for Rescue Percutaneous Coronary Intervention:
Underutilized and Underappreciated1877Ehtisham Mahmud, Mitul Patel
Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous
Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy:
A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study1880Larry R. Jackson II, Christine Ju, Marjorie Zettler, John C. Messenger, David J. Cohen,
Gregg W. Stone, Brian A. Baker, Mark Effron, Eric D. Peterson, Tracy Y. WangThe authors evaluated 11,756 acute myocardial infarction patients treated with percutaneous
coronary intervention at 233 hospitals in the United States enrolled in the TRANSLATE-ACS
(Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of
Treatment Patterns and Events After Acute Coronary Syndrome) registry to determine the risk of
Bleeding Academic Research Consortium (BARC) bleeding among patients discharged on triple
therapy with either clopidogrel or prasugrel. We found that the addition of an oral anticoagulant
was associated with a signiﬁcantly greater risk of any BARC-deﬁned bleeding relative to dual
antiplatelet therapy, regardless of which P2Y12 receptor inhibitor was selected. Among patients on
triple therapy, prasugrel use was associated with higher patient-reported–only bleeding, but not
bleeding requiring rehospitalization, than clopidogrel-treated patients.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Do Not Use Novel Antiplatelet Agents in Patients on Oral Anticoagulants After Stenting 1890
Freek W.A. VerheugtCONTINUED ON PAGE A-24
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DECEMBER 21, 2015 VOLUME 8, NUMBER 14PERIPHERAL 15-Year Patency and Life Expectancy After Primary Stenting Guided by
Intravascular Ultrasound for Iliac Artery Lesions in Peripheral Arterial Disease1893Hisao Kumakura, Hiroyoshi Kanai, Yoshihiro Araki, Yoshiaki Hojo, Toshiya Iwasaki,
Shuichi IchikawaFifteen-year patency, restenosis factors from intravascular ultrasound, and survival were evaluated
after primary stenting for 507 iliac lesions in patients with peripheral arterial disease. The 5-, 10-,
and 15-year primary patencies were 89%, 83%, and 75%, respectively, with no signiﬁcant
difference among TransAtlantic Inter-Society Consensus II categories. Post-procedural lumen area,
in-stent thrombosis, antiplatelet therapy discontinuation, and calciﬁed lesions were predictors of
primary patency. The 5-, 10-, and 15-year survival rates were 82%, 56%, and 40%. Age, critical
limb ischemia, diabetes, hemodialysis, and D-dimer level were predictors of overall survival.
Primary stenting for the iliac artery had favorable 15-year patency with improved life expectancy.n EDITORIAL COMMENT
Imaging-Guided Lower Extremity Endovascular Interventions: Is Now the Time? 1902
Mehdi H. Shishehbor, Shikhar AgarwalIMAGES IN
INTERVENTIONNot Your Typical Hole-in-the-Wall: Percutaneous Closure of an Acquired
Post-Myocardial Infarction Ventriculoatrial Gerbode Defect1905Richard Cheng, Reza Arsanjani, Emily Tat, Justin Cox, Abhimanyu Uberoi, Rebecca Aron,
Saibal Kar
Backward Migration of a MitraClip Through a Patent Transseptal Oriﬁce:
The Salmon Syndrome1907Christophe Caussin, Christelle Diakov, Patrice Dervanian, Nicolas AmabileCONTINUED ON PAGE A-25
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DECEMBER 21, 2015 VOLUME 8, NUMBER 14n ONLINE FEATURE Novel Percutaneous Apical Exclusion of a Left Ventricular
Pseudoaneurysm After Complicated Transapical Transcatheter Aortic Valve
Replacemente227Soraya Merchan, Chi-Hion Li, Francisco Javier Martinez, Chad Kliger, Vladimir Jelnin,
Gila Perk, Derek Brinster, Itzhak Kronzon, Carlos E. Ruiz
n ONLINE FEATURE Complete Transcatheter Treatment of Degenerated
Bioprosthetic Mitral Regurgitation: Transapical Paravalvular Leak Closure Followed
by Transseptal Mitral Valve-in-Valve Replacemente229Gagan D. Singh, Thomas W. Smith, Walter D. Boyd, Jeffrey A. Southard, Garrett B. Wong,
Femi Philip, Reginald I. Low, Jason H. Rogers
n ONLINE FEATURE Successful Endovascular Treatment of Unbenign
Spontaneous Dissection of the Left Internal Carotid Artery Combining Advanced
Carotid and Coronary Techniquese233Andrea Pacchioni, Tomoyuki Umemoto, Carlo Penzo, Salvatore Saccà, Jayme Ferro,
Alfredo Fede, Riccardo Turri, Bernhard Reimers
n ONLINE FEATURE Extremely Late Catch-Up Phenomenon After First-Generation
Sirolimus-Eluting Stent in the Left Main Stem: Insights From Optical Coherence
Tomographye237Toru Naganuma, Yusuke Fujino, Satoko Tahara, Satoru Mitomo, Sandeep Basavarajaiah,
Sunao Nakamura
n ONLINE FEATURE Transseptal Transcatheter Implantation of a Third-Generation
Balloon-Expandable Valve in Degenerated Mitral Bioprosthesise241David Jochheim, Alexander Khandoga, Axel Bauer, Moritz Baquet, Hans Theiss,
Jan Schenzle, Joerg Hausleiter, Steffen Massberg, Julinda Mehilli
n ONLINE FEATURE Simple Solution for anUndeﬂatable StentBalloon in theLeftMainStem e245
Jonathan Watt, Ayush Khurana, Javed M. Ahmed, Ian F. Purcell
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